Rituximab-induced Psoriasis in a Patient with Pemphigus Vulgaris: A Case Report and Literature Review

Overview

Journal Clin Case Rep

Date 2024 Mar 11

PMID 38464573

Authors

Leila Ghadirzade Arani

Shima Moslemi Haghighi

Soheila Nasiri

Sahar Dadkhahfar

Affiliations

Soon will be listed here.

Abstract

Key Clinical Message: Rituximab which is established as a main treatment for pemphigus vulgaris can be a potential causative factor for development of psoriasis in some patients. It is preferred to avoid using rituximab in patients who had a history of psoriasis. Acquainting medical doctors about rituximab-related cutaneous complications will help them in detection and management.

Abstract: Rituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface. Although it is used as promising treatment for pemphigus, nowadays it is also a new therapy for other autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis, and others like non-Hodgkin's lymphoma. Although there is increasing evidence regarding the safety and effectiveness of rituximab in these diseases, many cutaneous adverse effects have been reported. Here, we describe a 48-years-old patient affected with pemphigus vulgaris who developed psoriatic lesions on her on scalp, trunk, and extremities, 4 months after the second course of rituximab.

Citing Articles

Rituximab-induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review.

Ghadirzade Arani L, Moslemi Haghighi S, Nasiri S, Dadkhahfar S Clin Case Rep. 2024; 12(3):e8541.

PMID: 38464573 PMC: 10923702. DOI: 10.1002/ccr3.8541.

References

Hardcastle S, Gibbs S, Williamson L . Atypical psoriasis following rituximab for rheumatoid arthritis. J Rheumatol. 2012; 39(6):1303-4. DOI: 10.3899/jrheum.111256. View

Jayasekera P, Parslew R, Al-Sharqi A . A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab. Br J Dermatol. 2014; 171(6):1546-9. DOI: 10.1111/bjd.13146. View

Markatseli T, Kaltsonoudis E, Voulgari P, Zioga A, Drosos A . Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol. 2010; 27(6):996-8. View

Fiorillo L, Wang C, Hemmati I . Rituximab induced psoriasis in an infant. Pediatr Dermatol. 2014; 31(6):e149-51. DOI: 10.1111/pde.12437. View

Cohen J . Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis. 2008; 67(11):1647-8. DOI: 10.1136/ard.2007.085290. View

Balighi K, Daneshpazhooh M, Mahmoudi H, Tavakolpour S . Switching from pemphigus vulgaris to psoriasis: a rare report of three cases. Int J Dermatol. 2020; 59(5):e144-e146. DOI: 10.1111/ijd.14823. View

Guidelli G, Fioravanti A, Rubegni P, Feci L . Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Rheumatol Int. 2012; 33(11):2927-30. DOI: 10.1007/s00296-012-2581-3. View

Yokoo M, Oka D, Ueki H . Coexistence of psoriasis vulgaris and pemphigus foliaceus. Dermatologica. 1989; 179(4):222-3. DOI: 10.1159/000248369. View

Didona D, Di Zenzo G . Humoral Epitope Spreading in Autoimmune Bullous Diseases. Front Immunol. 2018; 9:779. PMC: 5913575. DOI: 10.3389/fimmu.2018.00779. View

10.

Mok M, Yeung C, Chan D, Lo W . New onset psoriasis after rituximab for treatment of idiopathic membranous nephropathy. Nephrology (Carlton). 2013; 19(1):60. DOI: 10.1111/nep.12147. View

11.

Ozen G, Ergun T, Oner S, Demirkesen C, Inanc N . Widespread psoriasis induced by rituximab in a patient with rheumatoid arthritis: an unexpected adverse reaction. Joint Bone Spine. 2013; 80(5):545-7. DOI: 10.1016/j.jbspin.2013.02.001. View

12.

Alahmari H, Alhowaish N, Omair M . Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab. Case Rep Rheumatol. 2019; 2019:5450863. PMC: 6855024. DOI: 10.1155/2019/5450863. View

13.

Yan L, Wang J, Zeng K . Association between HLA-DRB1 polymorphisms and pemphigus vulgaris: a meta-analysis. Br J Dermatol. 2012; 167(4):768-77. PMC: 3485671. DOI: 10.1111/j.1365-2133.2012.11040.x. View

14.

Singh F, Weinberg J . Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma. Cutis. 2005; 76(3):186-8. View

15.

Venables Z, Swart S, Soon C . Palmoplantar pustulosis secondary to rituximab: a case report and literature review. Clin Exp Dermatol. 2014; 40(4):451-2. DOI: 10.1111/ced.12527. View

16.

Ghadirzade Arani L, Moslemi Haghighi S, Nasiri S, Dadkhahfar S . Rituximab-induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review. Clin Case Rep. 2024; 12(3):e8541. PMC: 10923702. DOI: 10.1002/ccr3.8541. View

17.

Blauvelt A, Chiricozzi A . The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018; 55(3):379-390. PMC: 6244934. DOI: 10.1007/s12016-018-8702-3. View

18.

Zalzala H, Abdullah G, Abbas M, Mohammedsalih H, Mahdi B . Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients. Saudi Med J. 2018; 39(9):886-890. PMC: 6201012. DOI: 10.15537/smj.2018.9.23156. View

19.

Sanchez-Palacios C, Chan L . Development of pemphigus herpetiformis in a patient with psoriasis receiving UV-light treatment. J Cutan Pathol. 2004; 31(4):346-9. DOI: 10.1111/j.0303-6987.2004.0188.x. View

20.

Zhong W, Xu X, Zhu Z, Yang L, Du H, Xia Z . Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol. 2018; 52(5):1528-1538. PMC: 5873833. DOI: 10.3892/ijo.2018.4299. View